Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.

Sultan M, Vidovic D, Paine AS, Huynh TT, Coyle KM, Thomas ML, Cruickshank BM, Dean CA, Clements DR, Kim Y, Lee K, Gujar SA, Weaver ICG, Marcato P.

Stem Cells. 2018 May;36(5):641-654. doi: 10.1002/stem.2780. Epub 2018 Jan 30.

2.

Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis.

Warford JR, Lamport AC, Clements DR, Malone A, Kennedy BE, Kim Y, Gujar SA, Hoskin DW, Easton AS.

Acta Neuropathol Commun. 2018 Jan 4;6(1):4. doi: 10.1186/s40478-017-0506-9.

3.

Autophagic homeostasis is required for the pluripotency of cancer stem cells.

Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, Kim Y, Lee PW, Gujar SA.

Autophagy. 2017 Feb;13(2):264-284. doi: 10.1080/15548627.2016.1260808. Epub 2016 Dec 8.

4.

NAD+ salvage pathway in cancer metabolism and therapy.

Kennedy BE, Sharif T, Martell E, Dai C, Kim Y, Lee PW, Gujar SA.

Pharmacol Res. 2016 Dec;114:274-283. doi: 10.1016/j.phrs.2016.10.027. Epub 2016 Nov 2. Review.

PMID:
27816507
5.

A Qualitative Evaluation of Program Budgeting and Marginal Analysis in a Canadian Pediatric Tertiary Care Institution.

Smith N, Mitton C, Hiltz MA, Campbell M, Dowling L, Magee JF, Gujar SA.

Appl Health Econ Health Policy. 2016 Oct;14(5):559-68. doi: 10.1007/s40258-016-0250-5.

PMID:
27289589
6.

Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.

Coyle KM, Murphy JP, Vidovic D, Vaghar-Kashani A, Dean CA, Sultan M, Clements D, Wallace M, Thomas ML, Hundert A, Giacomantonio CA, Helyer L, Gujar SA, Lee PW, Weaver IC, Marcato P.

Oncotarget. 2016 Jul 12;7(28):44096-44112. doi: 10.18632/oncotarget.9858.

7.

All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy.

Clements DR, Kim Y, Gujar SA, Lee PW.

Oncoimmunology. 2015 Jun 5;5(1):e1057674. eCollection 2016.

8.

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PW.

Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953. Review.

9.

Introducing New Priority Setting and Resource Allocation Processes in a Canadian Healthcare Organization: A Case Study Analysis Informed by Multiple Streams Theory.

Smith N, Mitton C, Dowling L, Hiltz MA, Campbell M, Gujar SA.

Int J Health Policy Manag. 2015 Sep 24;5(1):23-31. doi: 10.15171/ijhpm.2015.169.

10.

The NAD(+) salvage pathway modulates cancer cell viability via p73.

Sharif T, Ahn DG, Liu RZ, Pringle E, Martell E, Dai C, Nunokawa A, Kwak M, Clements D, Murphy JP, Dean C, Marcato P, McCormick C, Godbout R, Gujar SA, Lee PW.

Cell Death Differ. 2016 Apr;23(4):669-80. doi: 10.1038/cdd.2015.134. Epub 2015 Nov 20.

11.

Olly Olly Oxen Free (or Ally Ally in Free): Playing Hide and Seek in Allocating Resources for Child and Youth Health.

Hiltz MA, Mitton C, Smith N, Dowling L, Campbell M, Magee JF, Gibson JL, Gujar SA, Levy A.

Healthc Q. 2015;18(2):36-9.

PMID:
26358999
12.

Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.

Garant KA, Shmulevitz M, Pan L, Daigle RM, Ahn DG, Gujar SA, Lee PW.

Oncogene. 2016 Feb 11;35(6):771-82. doi: 10.1038/onc.2015.136. Epub 2015 May 11.

PMID:
25961930
13.

Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN response.

Ahn DG, Sharif T, Chisholm K, Pinto DM, Gujar SA, Lee PW.

Cell Cycle. 2015;14(14):2301-10. doi: 10.1080/15384101.2015.1044187. Epub 2015 May 6.

14.

Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.

Clements DR, Sterea AM, Kim Y, Helson E, Dean CA, Nunokawa A, Coyle KM, Sharif T, Marcato P, Gujar SA, Lee PW.

J Immunol. 2015 May 1;194(9):4397-412. doi: 10.4049/jimmunol.1402132. Epub 2015 Mar 30.

15.

Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.

Mathenge EG, Dean CA, Clements D, Vaghar-Kashani A, Photopoulos S, Coyle KM, Giacomantonio M, Malueth B, Nunokawa A, Jordan J, Lewis JD, Gujar SA, Marcato P, Lee PW, Giacomantonio CA.

Neoplasia. 2014 Nov 20;16(11):950-60. doi: 10.1016/j.neo.2014.09.004. eCollection 2014 Nov.

16.

Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.

Marcato P, Dean CA, Liu RZ, Coyle KM, Bydoun M, Wallace M, Clements D, Turner C, Mathenge EG, Gujar SA, Giacomantonio CA, Mackey JR, Godbout R, Lee PW.

Mol Oncol. 2015 Jan;9(1):17-31. doi: 10.1016/j.molonc.2014.07.010. Epub 2014 Jul 24.

17.

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses.

Gujar SA, Clements D, Lee PW.

Oncoimmunology. 2014 Jan 1;3(1):e27622. Epub 2014 Jan 6.

18.

Oncolytic virus-mediated reversal of impaired tumor antigen presentation.

Gujar SA, Lee PW.

Front Oncol. 2014 Apr 10;4:77. doi: 10.3389/fonc.2014.00077. eCollection 2014. Review.

19.

The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Pan LZ, Ahn DG, Sharif T, Clements D, Gujar SA, Lee PW.

Cell Cycle. 2014;13(6):1041-8. doi: 10.4161/cc.28128. Epub 2014 Feb 7.

20.

Reovirus in cancer therapy: an evidence-based review.

Clements D, Helson E, Gujar SA, Lee PW.

Oncolytic Virother. 2014 Jul 9;3:69-82. doi: 10.2147/OV.S51321. eCollection 2014. Review.

21.

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.

Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW.

Br J Cancer. 2014 Jan 7;110(1):83-93. doi: 10.1038/bjc.2013.695. Epub 2013 Nov 26.

22.

Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.

Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW.

Cell Death Dis. 2013 Sep 5;4:e791. doi: 10.1038/cddis.2013.307.

23.
24.

Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Shmulevitz M, Gujar SA, Ahn DG, Mohamed A, Lee PW.

J Virol. 2012 Jul;86(13):7403-13. doi: 10.1128/JVI.00304-12. Epub 2012 Apr 24.

25.

Oncolytic virus-initiated protective immunity against prostate cancer.

Gujar SA, Pan DA, Marcato P, Garant KA, Lee PW.

Mol Ther. 2011 Apr;19(4):797-804. doi: 10.1038/mt.2010.297. Epub 2011 Jan 18.

26.

Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.

Gujar SA, Marcato P, Pan D, Lee PW.

Mol Cancer Ther. 2010 Nov;9(11):2924-33. doi: 10.1158/1535-7163.MCT-10-0590. Epub 2010 Oct 26.

27.

Pre-acute hepadnaviral infection is associated with activation-induced apoptotic death of lymphocytes in the woodchuck (Marmota monax) model of hepatitis B.

Gujar SA, Jenkins AK, Macparland SA, Michalak TI.

Dev Comp Immunol. 2010 Sep;34(9):999-1008. doi: 10.1016/j.dci.2010.05.001. Epub 2010 May 14.

PMID:
20451550
29.
30.

De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro.

MacParland SA, Pham TN, Gujar SA, Michalak TI.

J Gen Virol. 2006 Dec;87(Pt 12):3577-86.

PMID:
17098973
31.
32.

Characterization of bioactive recombinant woodchuck interleukin-2 amplified by RLM-RACE and produced in eukaryotic expression system.

Gujar SA, Michalak TI.

Vet Immunol Immunopathol. 2006 Aug 15;112(3-4):183-98. Epub 2006 Apr 24.

PMID:
16631932
33.

Supplemental Content

Loading ...
Support Center